ArticleAbdominal radiology (New York)2025
Retrospective cohort study on the efficacy and safety of high-intensity focused ultrasound in non-invasive treatment of uterine leiomyomas and adenomyosis.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Efficacy and Safety Evaluation of Focused Ultrasound Ablation Surgery Combined with Thermal Balloon Endometrial Ablation in Treating Adenomyosis: A Prospective Controlled Study.Gynecology and minimally invasive therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo assess the advantages of High-Intensity Focused Ultrasound (HIFU) in the treatment of uterine leiomyomas and adenomyosis.
methodsPatients with uterine leiomyomas (435 cases) and adenomyosis (78 cases) treated in our hospital from March 2020 to October 2023 were selected to receive non-invasive treatment with HIFU. Clinical symptom improvement and fibroid shrinkage were observed, and the incidence of complications and adverse reactions during and after treatment were analyzed.
resultsThe success rate of HIFU treatment in 435 cases of uterine leiomyomas was as high as 94.71%. The success rate of HIFU treatment was 96.15% in 78 cases of adenomyosis. Compared with before treatment, the improvement of clinical symptoms and the reduction of leiomyomas at one month, three months and six months after treatment were relatively better than those at the treatment period (P < 0.05). There were no serious adverse reactions in the patients during the treatment.
conclusionThe noninvasive application of HIFU on leiomyomas and adenomyosis effectively improves the clinical symptoms of patients, and the volume of fibroids decreases significantly. At the same time, HIFU is safe and worthy of clinical application.
Indexed as
Identifiers
40146310What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.